180 related articles for article (PubMed ID: 22629410)
1. Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study.
Dauksa A; Gulbinas A; Barauskas G; Pundzius J; Oldenburg J; El-Maarri O
PLoS One; 2012; 7(5):e37509. PubMed ID: 22629410
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation at selected CpG sites in peripheral blood leukocytes is predictive of gastric cancer.
Dauksa A; Gulbinas A; Endzinas Z; Oldenburg J; El-Maarri O
Anticancer Res; 2014 Oct; 34(10):5381-8. PubMed ID: 25275032
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma.
Omura N; Li CP; Li A; Hong SM; Walter K; Jimeno A; Hidalgo M; Goggins M
Cancer Biol Ther; 2008 Jul; 7(7):1146-56. PubMed ID: 18535405
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs.
Jansen M; Fukushima N; Rosty C; Walter K; Altink R; Heek TV; Hruban R; Offerhaus JG; Goggins M
Cancer Biol Ther; 2002; 1(3):293-6. PubMed ID: 12432281
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma.
Vincent A; Omura N; Hong SM; Jaffe A; Eshleman J; Goggins M
Clin Cancer Res; 2011 Jul; 17(13):4341-54. PubMed ID: 21610144
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
7. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma.
Ueki T; Toyota M; Skinner H; Walter KM; Yeo CJ; Issa JP; Hruban RH; Goggins M
Cancer Res; 2001 Dec; 61(23):8540-6. PubMed ID: 11731440
[TBL] [Abstract][Full Text] [Related]
9. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
House MG; Guo M; Iacobuzio-Donahue C; Herman JG
Carcinogenesis; 2003 Feb; 24(2):193-8. PubMed ID: 12584167
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
Sato N; Ueki T; Fukushima N; Iacobuzio-Donahue CA; Yeo CJ; Cameron JL; Hruban RH; Goggins M
Gastroenterology; 2002 Jul; 123(1):365-72. PubMed ID: 12105864
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of multiple genes in pancreatic adenocarcinoma.
Ueki T; Toyota M; Sohn T; Yeo CJ; Issa JP; Hruban RH; Goggins M
Cancer Res; 2000 Apr; 60(7):1835-9. PubMed ID: 10766168
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas.
Hong SM; Omura N; Vincent A; Li A; Knight S; Yu J; Hruban RH; Goggins M
Clin Cancer Res; 2012 Feb; 18(3):700-12. PubMed ID: 22173550
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
[TBL] [Abstract][Full Text] [Related]
16. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Nguyen C; Liang G; Nguyen TT; Tsao-Wei D; Groshen S; Lübbert M; Zhou JH; Benedict WF; Jones PA
J Natl Cancer Inst; 2001 Oct; 93(19):1465-72. PubMed ID: 11584062
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methylation profiling.
Endo Y; Fujimoto M; Ito N; Takahashi Y; Kitago M; Gotoh M; Hiraoka N; Yoshida T; Kitagawa Y; Kanai Y; Arai E
J Cancer Res Clin Oncol; 2021 May; 147(5):1341-1354. PubMed ID: 33635431
[TBL] [Abstract][Full Text] [Related]
20. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived.
Ueki T; Walter KM; Skinner H; Jaffee E; Hruban RH; Goggins M
Oncogene; 2002 Mar; 21(13):2114-7. PubMed ID: 11960385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
